Neurocrine Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 04, 2022 at 07:30 am EDT
Share
Neurocrine Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 310.6 million compared to USD 236.6 million a year ago. Net income was USD 13.9 million compared to USD 32.1 million a year ago. Basic earnings per share from continuing operations was USD 0.15 compared to USD 0.34 a year ago. Diluted earnings per share from continuing operations was USD 0.14 compared to USD 0.33 a year ago.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.